Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC-004 Monotherapy and with Budigalimab in Advanced Ovarian and Endometrial Cancers
NCT03138408Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jun 2017
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SC-004 in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more (2 arms), sponsored by AbbVie Inc. Primary endpoint: Dose-Limiting Toxicities at 21 days. Started Jun 2017; status: terminated.
02
Drugs
SC-004
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03138408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03138408.